Atrial Fibrillation Clinical Trial
— PREDIMAROfficial title:
Randomized Trial of Mediterranean Diet Plus Extravirgin Olive Oil in the Prevention of Recurrent Arrhythmias. The PREDIMAR (PREvención Con DIeta Mediterránea de Arritmias Recurrentes) Trial
Verified date | April 2020 |
Source | Fundación de investigación HM |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia and represents a
high priority public health problem, as in a few decades it will become a possibly
unsustainable load for the national health system. Preventive and therapeutic strategies
based on the best possible scientific evidence are required. Ablation therapy, despite being
the most effective approach, is associated with a 30-35% arrhythmic recurrence rate. An
intervention with Mediterranean diet and extra virgin olive oil (EVOO) has proven effective
in primary prevention and reduced the incidence of AF in high-risk subjects in a recent,
large, randomized trial (PREDIMED).
Methods: Parallel, randomized, multicenter nutritional intervention trial in 640 patients
with AF treated with catheter ablation. Two groups will be randomized in a 1:1 ratio: 1)
intervention with Mediterranean diet and EVOO; 2) usual care (control group). The primary
objective will be the incidence of atrial tachyarrhythmias for two years after ablation. At
least 190 recurrences are expected after 2 years (median) of follow-up. A relative risk of
0.7 is assumed and statistical power of 80%. Follow-up visits will be scheduled at 3, 6, 12,
18 and 24 months. In addition to the in-person visits, event monitors will be used to
document episodes. Dietary intervention will be carried out by nutritionists who will use
methods adapted from the PREDIMED trial with contacts every 2 months. 1 liter of EVOO per
week will be provided for free in the intervention arm. Inflammatory markers will be analyzed
in both groups during follow-up. Cox models will be used to estimate adjusted hazard ratios.
Status | Active, not recruiting |
Enrollment | 720 |
Est. completion date | January 31, 2022 |
Est. primary completion date | January 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Patients with symptomatic paroxysmal AF (with evidence of more than one symptomatic episode in the last year and at least one documented episode) upon whom catheter ablation is performed. - Patients with persistent symptomatic AF upon whom catheter ablation is performed. Exclusion Criteria: - Serious medical condition that prevents dietary intervention (gastrointestinal disease with intolerance to fats, advanced malignancy, neurological, psychiatric or severe endocrine disease) - Any other pathology or medical condition that limits survival to less than one year; Immunodeficiency or HIV-positive, - Consumption of illegal drugs, - Chronic alcoholism or total consumption of alcohol >80 g/d - Body mass index > 40 kg/m 2, - Difficulty or major inconvenience with changing dietary habits, inability to follow a style of Mediterranean diet, low probability of changing dietary habits according to the models of Prochaska and Diciemente (Nigg, 1999) - History of food allergy or hypersensitivity to any component of EVOO - Participation in a clinical trial carried out with drugs or use of a drug in experimental state during the year prior to inclusion - Institutionalized patients for chronic treatment, with lack of autonomy and with inability to perform the clinical follow-up, - Impossibility of telephone contact - Patients with acute infection or inflammatory process (e.g. pneumonia) may be included in the study three months after the resolution of the infectious symptoms. |
Country | Name | City | State |
---|---|---|---|
Spain | Teresa Barrio Lopez | Madrid | |
Spain | Teresa Barrio López | Madrid |
Lead Sponsor | Collaborator |
---|---|
Fundación de investigación HM | Hospital General Universitario de Alicante, University Hospital Virgen de las Nieves, University of Navarra |
Spain,
Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators — View Citation
Martínez-González MÁ, Toledo E, Arós F, Fiol M, Corella D, Salas-Salvadó J, Ros E, Covas MI, Fernández-Crehuet J, Lapetra J, Muñoz MA, Fitó M, Serra-Majem L, Pintó X, Lamuela-Raventós RM, Sorlí JV, Babio N, Buil-Cosiales P, Ruiz-Gutierrez V, Estruch R, Al — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | atrial tachyarrhythmias documented by electrocardiogram or recorder device | Atrial tachyarrhythmia is defined at any fast rate (>100 bpm) of supraventricular origin lasting more than 30 seconds and that is documented by ECG, Holter or event monitor. | mean follow up of 2 years | |
Secondary | Atrial fibrillation documented by electrocardiogram or recorder device | AF is defined at any irregular atrial rhythm lasting more than 30 seconds and that is documented by ECG, Holter or event monitor. AF may or may not be symptomatic. | mean follow up of 2 years | |
Secondary | changes in Inflammatory markers in blood samples | Prior to ablation blood samples will be collected for determination of inflammatory parameters in a subsample of the study (neutrophil to lymphocyte ratio, TNF-alpha, fibrinogen, IL-2, IL6, IL-8, C-reactive protein). At 3 and 12 months of follow-up the determination of these parameters will be repeated. | 1 year follow up | |
Secondary | Changes in quality of life measured by SF-36 questionnaire | Change in quality of life during the follow up measured by SF-36 questionnaire | mean follow up of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |